Joint initiative between Corning and Promega will exploit synergies to extend efforts in standardising and enhancing microarray processes
A new business alliance between Corning and Promega was announced recently.
The companies will co-develop, co-manufacture and co-market a fully optimised system of reagents for self-printing microarrays.
This alliance, which includes co-production of Pronto Plus systems, will contribute significantly to research efforts in gene expression analysis, particularly within the pharmaceutical industry.
Drawing on the synergy of technologies within Corning and Promega, it will offer microarray facilities the first ever, fully integrated system of slides and reagents, each being optimised for ease of use and reliability of results. "The synergy between the technologies of Promega and Corning provides the scientific community a unique blending of microarray technology, all in one system," said Martin Rosenberg, vice president of research and development at Promega.
The alliance closely follows Corning's entry into the reagent market with its Pronto microarray reagent systems for validation, printing and hybridisation.
The new integrated systems draw on Promega's expertise in RNA purification and labelling, and will include components from the SV Total RNA isolation system, ChipShot labelling system and ChipShot labelling cleanup system. "Through our customer contacts we recognized a need for a complete set of reagents that provides a fully optimised protocol from printing to hybridisation.
"We looked to Promega for its expertise in RNA purification and labeling to complement the Pronto reagents.
"The resulting Pronto Plus systems optimise input RNA quality, labelling efficiency and hybridisation background, giving a new level of sensitivity, reproducibility and success in DNA microarrays," said Pierce Baker, senior vice president, Corning Life Sciences.
